Osteoprotegerin reduces the loss of periarticular bone mass in primary and secondary spongiosa but does not influence inflammation in rat antigen-induced arthritis

Inflammation Research

Volumn 55, Issue 1, 2006, Pages 32-39

  Neumann, T ^a   Oelzner, P ^a   Petrow, P K ^a   Thoss, K ^a   Hein, G ^a   Stein, G ^a   Brauer R ^a  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

Author keywords

Antigen induced arthritis; Bone resorption; Bone turnover; Histomorphometry; Osteoprotegerin

Indexed keywords

OSTEOPROTEGERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN INDUCED ARTHRITIS; ARTHRITIS; ARTICLE; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; FEMALE; HISTOLOGY; INFLAMMATION; JOINT SWELLING; LUMBAR VERTEBRA; MORPHOMETRICS; NONHUMAN; OSSIFICATION; OSTEOLYSIS; RAT; STATISTICAL SIGNIFICANCE; SYNOVITIS; TIBIA; TRABECULAR BONE;

ANIMALS; ANTIGENS; ARTHRITIS, EXPERIMENTAL; BONE AND BONES; BONE DISEASES; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; KNEE JOINT; OSTEOPROTEGERIN; RATS; RATS, INBRED LEW; TIME FACTORS;

EID: 31344482169     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-005-0005-5     Document Type: Article

References (43)

1. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum 1997; 40: 5-18.
2. Deodhar AA, Woolf AD. Bone mass measurement and bone metabolism in rheumatoid arthritis: a review. Br J Rheumatol 1996; 35: 309-22.
3. Kroger H, Arnala I, Rehnberg V, Hamalainen M, Alhava E. Histomorphometry of periarticular bone in rheumatoid arthritis. Ann Chir Gynaecol 1994; 83: 56-62.
4. Shimizu S, Shiozawa S, Shiozawa K, Imura S, Fujita T. Quantitative histologic studies on the pathogenesis of periarticular osteoporosis in rheumatoid arthritis. Arthritis Rheum 1985; 28: 25-31.
5. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305-11.
6. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 1997; 390: 175-9.
7. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165-76.
8. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998; 95: 3597-602.
9. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM, et al. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. J Exp Med 1997; 186: 2075-80.
10. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 1999; 96: 3540-5.
11. Lum L, Wong BR, Josien R, Becherer JD, Erdjument-Bromage H, Schlondorff J, et al. Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)- converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival. J Biol Chem 1999; 274: 13613-8.
12. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999; 20: 345-57.
13. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309-19.
14. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998; 139: 1329-37.
15. Haynes DR, Crotti TN, Loric M, Bain GI, Atkins GJ, Findlay DM. Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. Rheumatology (Oxford) 2001; 40: 623-30.
16. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, et al. Activated T cells regulate bone loss and joint destraction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-9.
17. Wong BR, Josien R, Choi Y. TRANCE is a TNF family member that regulates dendritic cell and osteoclast function. J Leukoc Biol 1999; 65: 715-24.
18. Shigeyama Y, Pap T, Kunzler P, Simmen BR, Gay RE, Gay S. Expression of osteoclast differentiation factor in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2523-30.
19. Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, et al. Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 2000; 43: 259-69.
20. Itonaga I, Fujikawa Y, Sabokbar A, Murray DW, Athanasou NA. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000; 192: 97-104.
21. Brauer R, Henzgen S, Thoss K, Waldmann G. Changes of immunoregulatory properties and induction of autoimmune reactivity to cartilage in rabbits with antigen-induced arthritis. Exp Pathol 1990; 40: 35-44.
22. Thoss K, Henzgen S, Petrow PK, Katenkamp D, Brauer R. Immunomodulation of rat antigen-induced arthritis by leflunomide alone and in combination with cyclosporin A. Inflamm Res 1996; 45: 103-7.
23. Oelzner P, Brauer R, Henzgen S, Thoss K, Wunsche B, Hersmann G, et al. Periarticular bone alterations in chronic antigen-induced arthritis: free and liposome-encapsulated clodronate prevent loss of bone mass in the secondary spongiosa. Clin Immunol 1999; 90: 79-88.
24. Schalkwijk J, van den Berg WB, van de Putte LB, Joosten LA, van der Sluis M. Effects of experimental joint inflammation on bone marrow and periarticular bone. A study of two types of arthritis, using variable degrees of inflammation. Br J Exp Pathol 1985; 66: 435-44.
25. Romas E, Sims NA, Hards DK, Lindsay M, Quinn JW, Ryan PF, et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. Am J Pathol 2002; 161: 1419-27.
26. Campagnuolo G, Bolon B, Feige U. Kinetics of bone protection by recombinant osteoprotegerin therapy in Lewis rats with adjuvant arthritis. Arthritis Rheum 2002; 46: 1926-36.
27. Brauer R, Kette H, Henzgen S, Thoss K. Influence of cyclosporin A on cytokine levels in synovial fluid and serum of rats with antigen-induced arthritis. Agents Actions 1994; 41: 96-8.
28. Delling G. [Endocrine bone diseases morphology, histomorphometry and differential diagnosis (author's transl)]. Veroff Pathol 1975; 98: 1-111.
29. Murakami H, Nakamura T, Tsurukami H, Abe M, Barbier A, Suzuki K. Effects of tiludronate on bone mass, structure, and turnover at the epiphyseal, primary, and secondary spongiosa in the proximal tibia of growing rats after sciatic neurectomy. J Bone Miner Res 1994; 9: 1355-64.
30. Ma YF, Jee WS, Ke HZ, Lin BY, Liang XG, Li M, et al. Human parathyroid hormone-(1-38) restores cancellous bone to the immobilized, osteopenic proximal tibial metaphysis in rats. J Bone Miner Res 1995; 10: 496-505.
31. Erben RG, Kohn B, Rambeck WA, Zucker H. Histomorphometric analysis of the rat proximal tibial metaphysis by "linear scanning". Scanning Microsc 1990; 4: 625-38; discussion 638-40.
32. Aota S, Nakamura T, Suzuki K, Tanaka Y, Okazaki Y, Segawa Y, et al. Effects of indomethacin administration on bone turnover and bone mass in adjuvant-induced arthritis in rats. Calcif Tissue Int 1996; 59: 385-91.
33. Li J, Sarosi I, Yan XQ, Morony S, Capparelli C, Tan HL, et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 2000; 97: 1566-71.
34. Bendele A, McAbee T, Sennello G, Frazier J, Chlipala E, McCabe D. Efficacy of sustained blood levels of interleukin-1 receptor antagonist in animal models of arthritis: comparison of efficacy in animal models with human clinical data. Arthritis Rheum 1999; 42: 498-506.
35. Burgess TL, Qian Y, Kaufman S, Ring BD, Van G, Capparelli C, et al. The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts. J Cell Biol 1999; 145: 527-38.
36. Lacey DL, Tan HL, Lu J, Kaufman S, Van G, Qiu W, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol 2000; 157: 435-48.
37. Mori H, Kitazawa R, Mizuki S, Nose M, Maeda S, Kitazawa S. RANK ligand, RANK, and OPG expression in type II collagen-induced arthritis mouse. Histochem Cell Biol 2002; 117: 283-92.
38. Conway JG, Wakefield JA, Brown RH, Marron BE, Sekut L, Stimpson SA, et al. Inhibition of cartilage and bone destruction in adjuvant arthritis in the rat by a matrix metalloproteinase inhibitor. J Exp Med 1995; 182: 449-57.
39. Muller-Ladner U, Gay RE, Gay S. Molecular biology of cartilage and bone destruction. Curr Opin Rheumatol 1998; 10: 212-9.
40. van de Loo FA, Joosten LA, van Lent PL, Arntz OJ, van den Berg WB. Role of interleukin-1, tumor necrosis factor alpha, and interleukin-6 in cartilage proteoglycan metabolism and destruction. Effect of in situ blocking in murine antigen- and zymosan-induced arthritis. Arthritis Rheum 1995; 38: 164-72.
41. Weitzmann MN, Cenci S, Rifas L, Haug J, Dipersio J, Pacifici R. T cell activation induces human osteoclast formation via receptor activator of nuclear factor kappaB ligand-dependent and -independent mechanisms. J Bone Miner Res 2001; 16: 328-37.
42. Weryha G, Leclere J. Paracrine regulation of bone remodeling. Horm Res 1995; 43: 69-75.
43. Dempster DW. Exploiting and bypassing the bone remodeling cycle to optimize the treatment of osteoporosis. J Bone Miner Res 1997; 12: 1152-4.